While GIBCO has been known for almost 50 years as an industry leader for cell culture media, the move upstream into the creation of recombinant CHO cell lines is a more recent shift in product strategy. Beginning in 2009 with the launch of Life Technologies first integrated cell line kit (OptiCHO Protein Express), the strategy of creating platforms for biotherapeutic production has become a focus for the Grand Island, Bedford, and Frederick R&D teams. In line with this expanded R&D mission, we are excited to announce that Dr. Shue-Yuan Wang has joined the R&D team as the Director of Cell Line Development with responsibility for mammalian cell line products and services designed for biotherapeutic production. Shue has established a reputation as a thought leader in industrial cell culture and brings significant industry knowledge in therapeutic development through prior roles at Johnson and Johnson, Amgen, Abbott, and Human Genome Sciences. With multiple new kit launches scheduled over the next several years, this focus on industry leading platforms for biotherapeutics will expand GIBCO's future beyond our traditional cell culture media roots.
